— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected.
— Revenue grew 65% to $98.3 million vs. $97.76 million expected.
— For FY20, NUPLAZID sales is expected to be between $440 million and $470 million.
— For fiscal 2020, GAAP R&D expense is expected to be between $270 and $285 million and GAAP SG&A expense is expected to be between $440 and $460 million.
— ACAD shares rose about 4% following the earnings announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
